Cargando…
Efficacy of the NCCV Cocktail‐1 vaccine for refractory pediatric solid tumors: A phase I clinical trial
Pediatric refractory solid tumors are aggressive malignant diseases, resulting in an extremely poor prognosis. KOC1, FOXM1, and KIF20A are cancer antigens that could be ideal targets for anticancer immunotherapy against pediatric refractory solid tumors with positive expression for these antigens. T...
Autores principales: | Akazawa, Yu, Hosono, Ako, Yoshikawa, Toshiaki, Kaneda, Hide, Nitani, Chika, Hara, Junichi, Kinoshita, Yoshiaki, Kohashi, Kenichi, Manabe, Atsushi, Fukutani, Miki, Wakabayashi, Masashi, Sato, Akihiro, Shoda, Kayoko, Shimomura, Manami, Mizuno, Shoichi, Nakamoto, Yasunari, Nakatsura, Tetsuya |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6890444/ https://www.ncbi.nlm.nih.gov/pubmed/31571332 http://dx.doi.org/10.1111/cas.14206 |
Ejemplares similares
-
Phase I study of glypican-3-derived peptide vaccine therapy for patients with refractory pediatric solid tumors
por: Tsuchiya, Nobuhiro, et al.
Publicado: (2017) -
Higher human lymphocyte antigen class I expression in early‐stage cancer cells leads to high sensitivity for cytotoxic T lymphocytes
por: Akazawa, Yu, et al.
Publicado: (2019) -
Efficacy of immunotherapy targeting the neoantigen derived from epidermal growth factor receptor T790M/C797S mutation in non–small cell lung cancer
por: Akazawa, Yu, et al.
Publicado: (2020) -
Usefulness of serum microRNA as a predictive marker of recurrence and prognosis in biliary tract cancer after radical surgery
por: Akazawa, Yu, et al.
Publicado: (2019) -
A peptide antigen derived from EGFR T790M is immunogenic in non-small cell lung cancer
por: OFUJI, KAZUYA, et al.
Publicado: (2014)